The KNSTRN Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the human KNSTRN gene in HeLa cells. This product provides a heterogeneous pool of edited cells harboring target-gene disruption, enabling loss-of-function studies without clonal selection. The polyclonal format preserves genetic diversity and is suitable for pooled phenotypic analyses, drug sensitivity screens, and next-generation sequencing-based evaluations. CRISPR/Cas9-mediated gene disruption ablates kinastrin expression, offering a powerful tool to dissect its role in mitotic progression and chromosomal stability.
The host cell line, HeLa, is an immortalized human cervical adenocarcinoma epithelial cell line positive for human papillomavirus 18 (HPV-18). Inactivation of tumor suppressors p53 and Rb by viral oncoproteins drives a highly proliferative, aneuploid phenotype. These characteristics make HeLa cells a widely used model for cancer biology, particularly for investigating chromosome segregation defects and genomic instability. The inherently unstable karyotype of HeLa cells accentuates the consequences of mitotic regulator disruption, making them an ideal platform for studying KNSTRN function.
KNSTRN encodes kinastrin, a kinetochore-associated protein essential for faithful chromosome segregation. Kinastrin forms a complex with astrin (SPAG5) and SKAP to stabilize end-on kinetochore?Cmicrotubule attachments during mitosis. This complex is dynamically regulated by upstream kinases including CDK1?Ccyclin B and Aurora B, which phosphorylate kinastrin to modulate microtubule binding. Downstream, kinastrin promotes chromosome alignment and silences the spindle assembly checkpoint by recruiting PLK1 and antagonizing BUBR1. Interacting partners such as DYNLL1 dynein light chain further fine-tune kinetochore?Cmicrotubule dynamics. Disruption of KNSTRN leads to persistent checkpoint activation, chromosome misalignment, and aneuploidy.
In the HeLa background, KNSTRN knockout exacerbates inherent chromosomal instability, making this polyclonal population a valuable model for studying the mitotic checkpoint and mechanisms of aneuploidy in cancer. HeLa cells rely on robust spindle checkpoint signaling to maintain viability despite ongoing missegregation; loss of kinastrin elevates mitotic errors and sensitizes cells to microtubule poisons. Therefore, this knockout model can be used to explore synthetic lethal interactions and test mitotic inhibitor sensitivity, including taxanes and Aurora kinase inhibitors. The polyclonal nature captures diverse edit-induced phenotypes, providing a realistic representation of tumor heterogeneity.
Typical applications include investigating the spindle assembly checkpoint by monitoring BUBR1 and MAD2 levels via Western blotting, visualizing chromosome alignment errors with tubulin and CREST immunofluorescence, and quantifying ploidy alterations by flow cytometry. Live-cell microscopy can be employed to measure mitotic timing and segregation fidelity in real time. Genomic approaches such as RNA-seq enable transcriptome-wide impact assessment. These cells also serve in drug sensitivity assays to evaluate responses to anti-mitotic agents. For further information, please contact Ascent Research.
